Favorable longitudinal change of lung function in patients with asthma-COPD overlap from a COPD cohort

Respiratory Research

Table 3 Change in smoking status, use of ICS/LABA or ICS and moderate-to-severe exacerbation during the follow-up period

	Overall (N = 239)	Non-ACO COPD (n = 192)	ACO (n = 47)	P-value
Smoking Status				0.92
Continued smokers	8 (3.4)	6 (3.1)	2 (4.3)
Intermittent quitters	96 (40.2)	77 (40.1)	19 (40.4)
Sustained quitters	135 (56.5)	109 (56.8)	26 (55.3)
Use of ICS/LABA or ICS^a	159 (66.5)	125 (65.1)	34 (72.3)	0.35
Exacerbation^b
At least 2 incidents per year during follow-up	42 (17.6)	30 (15.6)	12 (25.5)	0.11

Data are presented as number (%)
Abbreviations: ACO asthma-chronic obstructive pulmonary disease overlap, COPD chronic obstructive lung disease, ICS inhaled corticosteroids, LABA long-acting β2-agonists
^aDefined as when the ICS/LABA or ICS was prescribed for longer than 2/3 of the study period
^bMedical history of hospital or emergency room visit for treatment because of one or more of the following: increased shortness of breath, increased sputum volume, and increased sputum purulence, which was assessed at every visit

ISSN: 1465-993X